Identification of the Cancer Cell Proliferation and Survival Functions of proHB-EGF by Using an Anti-HB-EGF Antibody

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Sato, Shuji ^a,b   Kamada, Hiroko ^b   Watanabe, Takahiro ^b   Tsuji, Isamu ^b   Fan, Jinhong ^a  

^a Takeda San Francisco Inc   (United States)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; ERLOTINIB; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY Y 073; MONOCLONAL ANTIBODY Y 142; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENETIC TRANSFECTION; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPHEROID CELL; STOMACH CANCER; TREATMENT RESPONSE; TUMOR GROWTH;

ANTIBODIES, ANTI-IDIOTYPIC; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84872653011     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054509     Document Type: Article

References (39)

1. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M, (1991) A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 251: 936-939.
2. Higashiyama S, Lau K, Besner GE, Abraham JA, Klagsbrun M, (1992) Structure of heparin-binding EGF-like growth factor. Multiple forms, primary structure, and glycosylation of the mature protein. J Biol Chem 267: 6205-6212.
3. Takenobu H, Yamazaki A, Hirata M, Umata T, Mekada E, (2003) The stress- and inflammatory cytokine-induced ectodomain shedding of heparin-binding epidermal growth factor-like growth factor is mediated by p38 MAPK, distinct from the 12-O-tetradecanoylphorbol-13-acetate- and lysophosphatidic acid-induced signaling cascades. J Biol Chem 278: 17255-17262.
4. Wang F, Liu R, Lee SW, Sloss CM, Couget J, et al. (2007) Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. Oncogene 26: 2006-2016.
5. Beerli RR, Hynes NE, (1996) Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities. J Biol Chem 271: 6071-6076.
6. Elenius K, Paul S, Allison G, Sun J, Klagsbrun M, (1997) Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J 16: 1268-1278.
7. Nanba D, Mammoto A, Hashimoto K, Higashiyama S, (2003) Proteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZF. J Cell Biol 163: 489-502.
8. Kinugasa Y, Hieda M, Hori M, Higashiyama S, (2007) The carboxyl-terminal fragment of pro-HB-EGF reverses Bcl6-mediated gene repression. J Biol Chem 282: 14797-14806.
9. Naglich JG, Metherall JE, Russell DW, Eidels L, (1992) Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. Cell 69: 1051-1061.
10. Raab G, Kover K, Paria BC, Dey SK, Ezzell RM, et al. (1996) Mouse preimplantation blastocysts adhere to cells expressing the transmembrane form of heparin-binding EGF-like growth factor. Development 122: 637-645.
11. Higashiyama S, Iwamoto R, Goishi K, Raab G, Taniguchi N, et al. (1995) The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor. J Cell Biol 128: 929-938.
12. Mitamura T, Iwamoto R, Umata T, Yomo T, Urabe I, et al. (1992) The 27-kD diphtheria toxin receptor-associated protein (DRAP27) from vero cells is the monkey homologue of human CD9 antigen: expression of DRAP27 elevates the number of diphtheria toxin receptors on toxin-sensitive cells. J Cell Biol 118: 1389-1399.
13. Shishido Y, Sharma KD, Higashiyama S, Klagsbrun M, Mekada E, (1995) Heparin-like molecules on the cell surface potentiate binding of diphtheria toxin to the diphtheria toxin receptor/membrane-anchored heparin-binding epidermal growth factor-like growth factor. J Biol Chem 270: 29578-29585.
14. Nakagawa T, Higashiyama S, Mitamura T, Mekada E, Taniguchi N, (1996) Amino-terminal processing of cell surface heparin-binding epidermal growth factor-like growth factor up-regulates its juxtacrine but not its paracrine growth factor activity. J Biol Chem 271: 30858-30863.
15. Takemura T, Kondo S, Homma T, Sakai M, Harris RC, (1997) The membrane-bound form of heparin-binding epidermal growth factor-like growth factor promotes survival of cultured renal epithelial cells. J Biol Chem 272: 31036-31042.
16. Iwamoto R, Handa K, Mekada E, (1999) Contact-dependent growth inhibition and apoptosis of epidermal growth factor (EGF) receptor-expressing cells by the membrane-anchored form of heparin-binding EGF-like growth factor. J Biol Chem 274: 25906-25912.
17. Miyoshi E, Higashiyama S, Nakagawa T, Hayashi N, Taniguchi N, (1997) Membrane-anchored heparin-binding epidermal growth factor-like growth factor acts as a tumor survival factor in a hepatoma cell line. J Biol Chem 272: 14349-14355.
18. Takemura T, Hino S, Murata Y, Yanagida H, Okada M, et al. (1999) Coexpression of CD9 augments the ability of membrane-bound heparin-binding epidermal growth factor-like growth factor (proHB-EGF) to preserve renal epithelial cell viability. Kidney Int 55: 71-81.
19. Tsuji I, Sato S, Otake K, Watanabe T, Kamada H, et al. (2012) Characterization of a variety of neutralizing anti-heparin-binding epidermal growth factor-like growth factor monoclonal antibodies by different immunization methods. mAbs 4: 732-739.
20. Miyagawa J, Higashiyama S, Kawata S, Inui Y, Tamura S, et al. (1995) Localization of heparin-binding EGF-like growth factor in the smooth muscle cells and macrophages of human atherosclerotic plaques. J Clin Invest 95: 404-411.
21. Sato S, Drake AW, Tsuji I, Fan J, (2012) A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF. PLoS One 7: e51964.
22. Plowman GD, Green JM, McDonald VL, Neubauer MG, Disteche CM, et al. (1990) The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity. Mol Cell Biol 10: 1969-1981.
23. Santini MT, Rainaldi G, (1999) Three-dimensional spheroid model in tumor biology. Pathobiology 67: 148-157.
24. Boatright KM, Salvesen GS, (2003) Mechanisms of caspase activation. Curr Opin Cell Biol 15: 725-731.
25. Higashiyama S, Iwabuki H, Morimoto C, Hieda M, Inoue H, et al. (2008) Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands. Cancer Sci 99: 214-220.
26. Hirata M, Umata T, Takahashi T, Ohnuma M, Miura Y, et al. (2001) Identification of serum factor inducing ectodomain shedding of proHB-EGF and studies of noncleavable mutants of proHB-EGF. Biochem Biophys Res Commun 283: 915-922.
27. Yamazaki S, Iwamoto R, Saeki K, Asakura M, Takashima S, et al. (2003) Mice with defects in HB-EGF ectodomain shedding show severe developmental abnormalities. J Cell Biol 163: 469-475.
28. Singh AB, Sugimoto K, Harris RC, (2007) Juxtacrine activation of epidermal growth factor (EGF) receptor by membrane-anchored heparin-binding EGF-like growth factor protects epithelial cells from anoikis while maintaining an epithelial phenotype. J Biol Chem 282: 32890-32901.
29. Friedrich J, Ebner R, Kunz-Schughart LA, (2007) Experimental anti-tumor therapy in 3-D: spheroids - old hat or new challenge? Int J Radiat Biol 83: 849-871.
30. Naef M, Yokoyama M, Friess H, Büchler MW, Korc M, (1996) Co-expression of heparin-binding EGF-like growth factor and related peptides in human gastric carcinoma. Int J Cancer 66: 315-321.
31. Thøgersen VB, Sørensen BS, Poulsen SS, Ørntoft TF, Wolf H, et al. (2001) A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res 61: 6227-6233.
32. Kobrin MS, Funatomi H, Friess H, Buchler MW, Stathis P, et al. (1994) Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. Biochem Biophys Res Commun 202: 1705-1709.
33. Suo Z, Risberg B, Karlsson MG, Villman K, Skovlund E, et al. (2002) The expression of EGFR family ligands in breast carcinomas. Int J Surg Pathol 10: 91-99.
34. Miyamoto S, Hirata M, Yamazaki A, Kageyama T, Hasuwa H, et al. (2004) Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res 64: 5720-5727.
35. Mishima K, Higashiyama S, Asai A, Yamaoka K, Nagashima Y, et al. (1998) Heparin-binding epidermal growth factor-like growth factor stimulates mitogenic signaling and is highly expressed in human malignant gliomas. Acta Neuropathol 96: 322-328.
36. Lin J, Hutchinson L, Gaston SM, Raab G, Freeman MR, (2001) BAG-1 is a novel cytoplasmic binding partner of the membrane form of heparin-binding EGF-like growth factor: a unique role for proHB-EGF in cell survival regulation. J Biol Chem 276: 30127-30132.
37. Hieda M, Isokane M, Koizumi M, Higashi C, Tachibana T, et al. (2008) Membrane-anchored growth factor, HB-EGF, on the cell surface targeted to the inner nuclear membrane. J Cell Biol 180: 763-769.
38. Shimura T, Yoshida M, Fukuda S, Ebi M, Hirata Y, et al. (2012) Nuclear translocation of the cytoplasmic domain of HB-EGF induces gastric cancer invasion. BMC Cancer 12: 205.
39. Mort JS, Buttle DJ, (1999) The use of cleavage site specific antibodies to delineate protein processing and breakdown pathways. Mol Pathol 52: 11-18.